Scemblix (asciminib) is a new first-line option for adults with newly diagnosed Philadelphia chromosome-positive chronic ...

Regulators are also reviewing Teva’s application for its Prolia biosimilar candidate. The FDA’s decisions are expected ...

PTC Therapeutics' NDA resubmission of Translarna was based on data from Study 041 and the long-term STRIDE registry. No PDUFA action date was provided for regulators.

Artificial intelligence stands out as a particularly promising solution to the challenges of improving health literacy.

Prademagene zamikeracel (pz-cel) could be a new treatment for rare genetic disease recessive dystrophic epidermolysis bullosa (RDEB).

The effects of breast cancer can remain long after the disease has left the body, serving as a traumatic daily reminder.

Qsymia’s manufacturer also released postmarketing data showing the oral therapy for weight loss was associated with ...

A single-center retrospective study found the approval and use of new agents to treat chronic graft-versus-host disease (GVHD ...

Each Sunday we feature a highlight reel of various articles posted on our website that week. Some prior research had shown ...

More Treatment Options for Schizophrenia, More Decisions About Which One to Choose | AMCP Nexus 2024 ...

This week’s approval expands Seldardsi indications to treat adults with Crohn’s disease and ulcerative colitis.